The Presidium of the Russian IP Court has confirmed the right to use inventions for the dapagliflozin compound and a pharmaceutical composition containing dapagliflozin
On March 10, 2026, the Presidium of the Russian IP Court considered the cassation appeals of the foreign entity AstraZeneca AB and AstraZeneca Pharmaceuticals LLC against the decision of the IP Court dated December 02, 2025, in case No. SIP-298/2025. Following the review, the cassation court upheld the decision of the court of first instance and dismissed the appeals.